PCSA Earnings

Quarterly EPS
$-25.25
Q2 2024
$-25.75
Q3 2024
$-19.39
Q4 2024
$-7.58
Q1 2025
$-6.25
Q2 2025
$-1.75
Q3 2025
$-1.44
Q4 2025
$-1.29
Q1 2026
Latest RevenueN/A
Latest Net Income-3377179
EPS & Revenue Trend
PeriodEPSRevenueNet IncomeRev YoYEPS YoY
Q1 2026-$1.290-3377179+83.0%
Q4 2025-$1.440-3358938+92.6%
Q3 2025-$1.750-3436573+93.2%
Q2 2025-$6.250-3933918+75.2%
Q1 2025-$7.580-2834405+72.7%
Q4 2024-$19.390-2728708+54.5%
Q3 2024-$25.750-3384703+33.1%
Q2 2024-$25.250-3010326+47.9%
Q1 2024-$27.750-2726381
Q4 2023-$42.620-2404931
Q3 2023-$38.500-2081951
Q2 2023-$48.500-2612565
Processa Pharmaceuticals, Inc. Common (PCSA) — Earnings